The impact of biofilm on cefotaxime killing effect against Escherichia coli
Keywords:
biofilm, cefotaxime, E. coli, MIC, MBIC, infectionAbstract
Biofilms cause chronic infections that are difficult to treat because of the resistance of microorganisms inside them. The goal is to assess the killing potential of cefotaxime against Escherichia coli in biofilms obtained from clinical isolates kept in the clinical microbiology laboratory of Dr. Soetomo Surabaya Hospital. The study was conducted by laboratory experimental design. Two steps challenged the bacterial isolates by applying cefotaxime to the planktonic bacterial state and the biofilm state. Minimum inhibitory concentration (MIC), minimum biofilm inhibitory concentration (MBIC), minimum bactericidal concentration (MBC) and minimum biofilm eradication concentration (MBEC) were used as an indicator for comparison. Nineteen isolates of E coli were used for this experiment, 7 isolates with MIC of 0.125-0.25 μg/ml (36,84%), 6 isolates with MBC value 0.25-0.5 μg/ml (31,57%). The MBIC > 128 μg/ml is 6 isolates (31,57%), MBEC > 128 μg/ml is 14 isolates (73,68%). Cefotaxime had lower killing efficacy against E. coli in biofilm than in the planktonic phase. MBIC of E. coli requires cefotaxime at minimal 5 times two-fold increase from MIC, with an average 7-8 times. MBEC of E. coli requires cefotaxime concentration minimal 5 times two-fold dilution increase from MBC, with an average 8 - 9 times.
Downloads
References
Akbarov, A. N., & Xabilov, D. N. U. (2021). The condition of the oral cavity in patients who have had a viral infection COVID-19. International Journal of Health & Medical Sciences, 4(4), 381-383. https://doi.org/10.21744/ijhms.v4n4.1796
Akova M. Epidemiology of antimicrobial resistance in bloodstream infections. Virulence. 2016;7(3):252–66. http://dx.doi.org/10.1080/21505594.2016.1159366
Allison DG, Gilbert P. Bacterial biofilms. Vol. 76, Science Progress. 1992. 305–321 p.
Anwar H, Van Biesen T, Dasgupta M, Lam K, Costerton JW. Interaction of biofilm bacteria with antibiotics in a novel in vitro chemostat system. Antimicrobial Agents Chemotheraphy. 1989;33(10):1824–6.
Azeredo J, Azevedo NF, Briandet R, Cerca N, Coenye T, Costa AR, et al. Critical review on biofilm methods. Crit Rev Microbiol. 2017;43(3):313–51. https;//10.1080/1040841X.2016.1208146
Beloin C, Roux A, Ghigo JM. Escherichia coli biofilms. Curr Top Microbiol Immunol. 2008;322:249–89. https://doi.org/10.1007/978-3-540-75418-3_12
Brady RA, Calhoun JH, Leid JG, Shirtliff ME. Infections of Orthopaedic Implants and Devices. The Role of Biofilms in Device-Related Infections. 2008. 15–55 p. https://doi.org/10.0.3.239/978-3-540-68119-9_2
Bryers JD. Medical biofilms. Biotechnol Bioeng. 2008;100(1):1–18. https://doi.org/10.1002/bit.21838
Bueno J. Anti-Biofilm Drug Susceptibility Testing Methods: Looking for New Strategies against Resistance Mechanism. Journal Microbiology Biochemistry Technology. 2011;s3. https://doi.org/10.0.16.76/1948-5948.s3-004
CDC. National Infection & Death Estimates for Antibiotic Resistance. 2019.
Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37(6):1771–6. https://doi.org/10.1128/jcm.37.6.1771-1776.1999
Chen XP, Ali L, Wu LY, Liu C, Gang CX, Huang QF, et al. Biofilm formation plays a role in the formation of multidrug-resistant Escherichia coli toward nutrients in microcosm experiments. Front Microbiol. 2018;9(MAR):1–9. https://doi.org/10.0.13.61/fmicb.2018.00367
CLSI. M100 Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute P:; 2021.
CLSI. Manual Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards - 7a ed. Document M7-A7 performance standards for antimicrobial susceptibility testing. Vol. 26 No. 2006.
CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically ; Approved Standard — Ninth Edition. Vol 32 no 2, editor. Vol. 32. CLSI; 2012.
Crabbé A, Jensen PØ, Bjarnsholt T, Coenye T. Antimicrobial Tolerance and Metabolic Adaptations in Microbial Biofilms. Trends Microbiol. 2019;27(10):850–63. https://doi.org/10.1016/j.tim.2019.05.003
Desai M, Bühler T, Weller PH, Brown MRW. Increasing resistance of planktonic and biofilm cultures of Burkholderia cepacia to ciprofloxacin and ceftazidime during exponential growth. J Antimicrob Chemother. 1998;42(2):153–60. https://doi.org/10.1093/jac/42.2.153
Dincer S, Masume FU, Delik A. Antibiotic Resistance in Biofilm. In: IntechOpen. 2020. p. 13. http://dx.doi.org/10.5772/intechopen.92388
Donlan RM. Biofilm formation: A clinically relevant microbiological process. Clinical Infectius Disease. 2001;33(8):1387–92. https://doi.org/10.1086/322972
Donlan RM. Biofilms and device-associated infections. Emerg Infect Dis. 2001;7(2):277–81. https;//doi.org/10.3201/eid0702.010226
Donlan RM. Role of Biofilms in Antimicrobial Resistance : ASAIO Journal. ASAIO J. 2000;46(6):S47-52. https://journals.lww.com/asaiojournal/Fulltext/2000/11000/Role_of_Biofilms_in_Antimicrobial_Resistance 37.aspx
Duguid IG, Evans E, Brown MRW, Gilbert P. Growth-rate-independent killing by ciprofloxacin of biofilm-derived staphylococcus epidermidis evidence for cell-cycle dependency. J Antimicrob Chemother. 1992;30(6):791–802. https://doi.org/10.1093/jac/30.6.791
Fawzy S, Abdel-Latif W, Gamal R. Comparison between Antimicrobial Minimal Biofilm Eradication Concentration and Minimal Inhibitory Concentration in Clinical Isolates in Device Related Infections. Egypt J Med Microbiol. 2016;25(1):91–100. https://doi.org/10.12816/0037097
Fawzy S, Abdel-Latif W, Gamal R. Comparison between Antimicrobial Minimal Biofilm Eradication Concentration and Minimal Inhibitory Concentration in Clinical Isolates in Device Related Infections. Egypt J Med Microbiol. 2016;25(1):91–100. https://doi.org/10.0.50.16/0037097
Frost I, Van Boeckel TP, Pires J, Craig J, Laxminarayan R. Global geographic trends in antimicrobial resistance: The role of international travel. J Travel Med. 2019;26(8):1–13. https://doi.org/10.1093/jtm/taz036
Grayson ML, Crowe S, McCarthy J, Mills J, Mouton J, Norrby SR, et al. Kucers’ The Use of Antibiotics. seventh ed. M. Linday Grayson, editor. Kucers’ The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs. London: Taylor & Francis Group; 2010.
Gupta A. Biofilm Quantification and Comparative Analysis of MIC (Minimum Inhibitory Concentration) & MBIC (Minimum Biofilm Inhibitory Concentration) Value for Different Antibiotics against E. coli. Int J Curr Microbiol Appl Sci. 2015;4(2):198–224. http://www.ijcmas.com
He X, Lu F, Yuan F, Jiang D, Zhao P, Zhu J, et al. Biofilm formation caused by clinical Acinetobacter baumannii isolates is associated with overexpression of the AdeFGH efflux pump. Antimicrob Agents Chemother. 2015;59(8):4817–25.
Jamal M, Ahmad W, Andleeb S, Jalil F, Imran M, Nawaz MA, et al. Bacterial biofilm and associated infections. Journal Chinese Medical Association. 2018;81(1):7–11. https://doi.org/10.1016/j.jcma.2017.07.012
Katzung BG. Basic & Clinical Pharmacology, Fourteenth Edition. Basic and Clinical Pharmacology. McGrowHill; 2018. p1497–1509.
Kharazmi A, Giwercman B, Høiby N. Robbins device in biofilms research. Methods Enzymol. 1999;310(1980):207–15. https://doi.org/10.1016/S0076-6879(99)10018-1
Macià MD, Rojo-Molinero E, Oliver A. Antimicrobial susceptibility testing in biofilm-growing bacteria. Clinical Microbiology Infection. 2014;20(10):981–90. https://dx.doi.org/10.1111/1469-0691.12651
Macià MD, Rojo-Molinero E, Oliver A. Antimicrobial susceptibility testing in biofilm-growing bacteria. Clin Microbiol Infect. 2014;20(10):981–90. https://doi.org/10.0.4.87/1469-0691.12651
Mandakhalikar KD, Rahmat JN, Chiong E, Neoh KG, Shen L, Tambyah PA. Extraction and quantification of biofilm bacteria: Method optimized for urinary catheters. Sci Rep. 2018;8(1):1–9. https://doi.org/10.1038/s41598-018-26342-3
Montanaro L, Poggi A, Visai L, Ravaioli S, Campoccia D, Speziale P, et al. Extracellular DNA in biofilms. Int J Artif Organs. 2011;34(9):824–31. https://doi.org/10.5301/ijao.5000051
Mulla S, Kumar A, Rajdev S. Comparison of MIC with MBEC Assay for in Vitro Antimicrobial Susceptibility Testing in Biofilm Forming Clinical Bacterial Isolates. Adv Microbiol. 2016;06(02):73–8. https://doi.org/10.4236/aim.2016.62007
Naves P, Del Prado G, Ponte C, Soriano F. Differences in the in vitro susceptibility of planktonic and biofilm-associated Escherichia coli strains to antimicrobial agents. J Chemother. 2010;22(5):312–7. https://doi.org/10.1179/joc.2010.22.5.312
Percival SL, Suleman L, Vuotto C, Donelli G. Healthcare-Associated infections, medical devices and biofilms: Risk, tolerance and control. Journal Medical Microbiology. 2015;64(4):323–34.
Ponnusamy P, Natarajan V, Sevanan M. In vitro biofilm formation by uropathogenic Escherichia coli and their antimicrobial susceptibility pattern. Asian Pac J Trop Med [Internet]. 2012;5(3):210–3. http://dx.doi.org/10.1016/S1995-7645(12)60026-1
Poovendran P, Ramanathan N. In vitro study on antibiotic susceptibility pattern of biofilm producing Uropathogenic Escherichia coli isolates and their molecular characterization. Asian J Pharm Clin Res. 2014;7(3):181–5.
Rafaque Z, Abid N, Liaqat N, Afridi P, Siddique S, Masood S, et al. In-vitro investigation of antibiotics efficacy against uropathogenic Escherichia coli biofilms and antibiotic induced biofilm formation at subminimum inhibitory concentration of ciprofloxacin. Infect Drug Resist. 2020;13:2801–10. https://doi.org/10.0.8.99/IDR.S258355
Ripolles-avila C, Fontecha-uma F, R AG. Biofilms in the Spotlight : Detection , Quantification , and Removal Methods. Compr Rev Food Sci Food Saf. 2018;17.
Sharma G, Sharma S, Sharma P, Chandola D, Dang S, Gupta S, et al. Escherichia coli biofilm: development and therapeutic strategies. J Appl Microbiol. 2016;121(2):309–19
Singh R, Ray P, Das A, Sharma M. Role of persisters and small-colony variants in antibiotic resistance of planktonic and biofilm-associated Staphylococcus aureus: An in vitro study. J Med Microbiol. 2009;58(8):1067–73.
Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358(9276):135–8.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864
T. Salih M, F. AL-Ani N. Microbiological Aspects in Biofilm Produced by some Uropathogens Isolated from Patients with Indwelling Bladder Catheters. Rafidain J Sci. 2013;24(1):1–16.
Thieme L, Hartung A, Tramm K, Klinger-Strobel M, Jandt KD, Makarewicz O, et al. MBEC Versus MBIC: The Lack of Differentiation between Biofilm Reducing and Inhibitory Effects as a Current Problem in Biofilm Methodology. Biol Proced Online. 2019;21(1):1–5. https://doi.org/10.1186/s12575-019-0106-0
Trafny EA. Biofilms and their role in infection pathogenesis. Postep Mikrobiol. 2008;47(3).
Tutulan R. Impact of Biofilm Formation and Composition on Antibiotic Resistance in Environmental Isolates of Escherichia coli and Salmonella spp . Canada; 2015. (PhD).
Vickery K, Hu H, Jacombs AS, Bradshaw DA, Deva AK. A review of bacterial biofilms and their role in device-associated infection. Healthc Infect. 2013;18(2):61–6.
Wilson C, Lukowicz R, Merchant S, Valquier-Flynn H, Caballero J, Sandoval J, et al. Quantitative and Qualitative Assessment Methods for Biofilm Growth: A Mini-review. Res Rev J Eng Technol. 2017;6(4). http://www.ncbi.nlm.nih.gov/pubmed/30214915%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6133255
Zhao X, Yu Z, Ding T. Quorum-sensing regulation of antimicrobial resistance in bacteria. MDPI. 2020;8(3):1–21. www.mdpi.com/journal/mocroorganisms
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. http://dx.doi.org/10.1016/S0140-6736(20)30566-3
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
